CEO Peter Guenter to leave almirall on 31/12/2020 to pursue new opportunities

Peter Guenter, CEO, has decided to leave Almirall at the end of this year to pursue a new opportunity at a larger company. He will continue to lead Almirall for the next 3 months and will actively assist the company in anyway possible.

Jorge Gallardo Ballart, Chairman of the Board of Directors, commented: “We regret Peter’s decision to pursue new opportunities. On behalf of the Board of Directors and the employees of Almirall I want to thank Peter for the impressive transformation he spearheaded at Almirall over the last years. Core Ebitda will have quadrupled, we have now one of the strongest late stage pipelines in the medical dermatology space, and we have launched successfully Ilumetri and Skilarence in Europe and Seysara in the US. Last but not the least, the company has been strengthened by the recruitment and development of talented employees in various parts of the organisation. We wish Peter all the best in his new endeavours and have initiated the process to identify Peter’s successor.

Peter Guenter, CEO, commented: “to leave Almirall has not been an easy decision because of the great momentum that we all have created at Almirall. The company is in a much better position than it was three years ago and is poised for significant expansion with a best in class portfolio in Medical Dermatology. I want to thank the Chairman and my colleagues at the Board of Directors for the confidence and support that I have always received over the last three years.

Most importantly, I am very grateful and proud of all my colleagues at ALMIRALL who have done such a wonderful job in transforming the company into a leader in the field of Medical Dermatology. Together we have forged a strong company helping patients suffering from severe dermatological conditions”. The process to identify his successor has been set in motion.

About Almirall

Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient’s needs through science to improve their lives. Our Noble Purpose is at the core of our work: “Transform the patients' world by helping them realize their hopes and dreams for a healthy life”. We invest in differentiated and ground-breaking medical dermatology products to bring our innovative solutions to patients in need.

The company, founded in 1943 and headquartered in Barcelona, is publically traded on the Spanish Stock Exchange and is a member of the IBEX35 (ticker: ALM). Throughout its 77-year history, Almirall has retained a strong focus on the needs of patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, through 13 subsidiaries, with about 1,800 employees. Total revenues in 2019 were 908.4 million euros.

For more information, please visit almirall.com